Aramchol™ reduces fibrosis progression in 24 weeks
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) | Clinical Research Trial Listing ( Nonalcoholic Steatohepatitis (NASH) ) ( NCT04104321 )
Galmed: A Deep-Dive Analysis Of The ARREST Trial (NASDAQ:GLMD) | Seeking Alpha
Drug discovery and treatment paradigms in nonalcoholic steatohepatitis - Noureddin - 2020 - Endocrinology, Diabetes & Metabolism - Wiley Online Library
Galmed closes patient enrolment for Phase IIb ARREST study of Aramchol to treat liver diseases - Clinical Trials Arena
Identification of serum biomarkers associated with Aramchol treatment.... | Download Scientific Diagram
Aramchol attenuated lipid accumulation and ROS production in... | Download Scientific Diagram
Frontiers | Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments | Pharmacology
FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease - Clinical Gastroenterology and Hepatology
Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis - JHEP Reports
Multicenter Trial png images | PNGWing
One-year results of the Global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol, a Stearoyl CoA Desaturasemodulator in NASH patients
Aramchol - Wikipedia
IJERPH | Free Full-Text | Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives | HTML
Galmed And Aramchol In NASH: Moving On Higher (NASDAQ:GLMD) | Seeking Alpha
An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents
Frontiers | Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments | Pharmacology
Therapeutic pipeline in nonalcoholic steatohepatitis | Nature Reviews Gastroenterology & Hepatology
Diabetes & Metabolism Journal
New Data on Aramchol TM for the Treatment of Non-alcoholic Steatohepatitis: Exploring Potential for Greater Efficacy and the Effect on Glucose Metabolism - European Medical Journal
F-1 1 v367324_f1.htm FORM F-1 As
One-year results of the Global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol, a Stearoyl CoA Desaturasemodulator in NASH patients
